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Abstract
Genome-wide association studies (GWAS) have identified hundreds of associated loci across many common diseases. Most
risk variants identified by GWAS will merely be tags for as-yet-unknown causal variants. It is therefore possible that
identification of the causal variant, by fine mapping, will identify alleles with larger effects on genetic risk than those
currently estimated from GWAS replication studies. We show that under plausible assumptions, whilst the majority of the
per-allele relative risks (RR) estimated from GWAS data will be close to the true risk at the causal variant, some could be
considerable underestimates. For example, for an estimated RR in the range 1.2–1.3, there is approximately a 38% chance
that it exceeds 1.4 and a 10% chance that it is over 2. We show how these probabilities can vary depending on the true
effects associated with low-frequency variants and on the minor allele frequency (MAF) of the most associated SNP. We
investigate the consequences of the underestimation of effect sizes for predictions of an individual’s disease risk and
interpret our results for the design of fine mapping experiments. Although these effects mean that the amount of
heritability explained by known GWAS loci is expected to be larger than current projections, this increase is likely to explain
a relatively small amount of the so-called ‘‘missing’’ heritability.
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Introduction
Genome-wide association studies (GWAS) have been extremely
successful across many diseases in identifying loci harbouring
genetic variants that affect disease susceptibility. Virtually all
associated variants identified from GWAS to date have relatively
small effects: each additional copy of the risk allele typically
increases disease risk by 10%–30% (see for example [1]). It has
become clear that the variants discovered thus far account for only
a small proportion of the genetic basis of each of the diseases, and
there has been considerable speculation about where the
‘‘missing’’ heritability might lie [1].
One of several important factors in the success of the GWAS
design has been the pattern of linkage disequilibrium in human
populations. The strong correlations between nearby SNPs mean
that commercially available genotyping chips, which assay
300,000–1,000,000 SNPs, can capture much of the common
variation in the human genome, particularly in Caucasian
populations [2]. Because genotypes at the causative loci will often
be correlated with those at SNPs that are typed on the genotyping
chip, it is typically not necessary to assay the true causative variant
directly in order to detect a genetic association with disease.
While linkage disequilibrium is extremely helpful for GWAS
discovery, the downside is that in most reported regions of
association, the true causal variant or variants remain unknown.
Therefore it is possible that many of the associated SNPs are only
surrogates for the true causal variant(s). When it comes to
quantifying the genetic effect, the genotype at the reported SNP
acts as a noisy measurement of the genotype at the causal variant.
This noise can dilute the apparent strength of the effect, and
obscure the true relationship between genotype and phenotype. As
we progress towards the identification of the causal variants,
estimates of effect sizes for associated loci will thus tend to increase.
In turn, the proportion of disease susceptibility explained by
GWAS loci will also increase. Thus in addition to other plausible
sources, such as secondary signals in GWAS loci, rare variants
(,1% frequency), copy number polymorphisms, and epigenetic
effects, some of the missing heritability is actually contained in loci
already identified by GWAS, and is driven by common variation
(.1% frequency).
In this paper we use an extensive simulation study to investigate,
and quantify, this phenomenon. We show that estimates of the size
of the genetic effect based on the best SNP from the GWAS
genotyping chip can often closely approximate the effect size at the
true causal SNP. In some cases the causal SNP has a large effect
and is poorly tagged, leading to substantial underestimation of the
true effect size. We investigate how much of the ‘‘missing’’
heritability could thus be hidden in reported GWAS loci, under
several sets of assumptions about the nature of the effects at true
causal SNPs. Our results also inform the design and value of fine
mapping experiments in GWAS loci.
Results
Patterns of linkage disequilibrium (LD) in human populations
are complicated, and preclude analytical results, so we adopted a
PLoS Genetics | www.plosgenetics.org 1 March 2011 | Volume 7 | Issue 3 | e1001337simulation approach (see Methods for details). We describe the
approach informally before describing our results. First, we chose
each allele at each SNP in the HapMap ENCODE regions in turn,
assuming it to be causative with a given effect size. We then used a
previously reported simulation scheme (HAPGEN, [3]) to simulate
a large population of chromosomes with European ancestry,
whose patterns of LD match those in the CEU HapMap analysis
panel. From this population a case-control sample is taken, with
the controls sampled randomly from the population and the cases
chosen by oversampling chromosomes carrying the causal allele in
the appropriate way given its frequency and assumed effect size.
To simulate a GWAS, we considered samples of 2000 cases and
2000 controls typed on the Affymetrix GeneChip Human
Mapping 500K Array Set (see www.affymetrix.com). No single
sample size can model all reported GWAS, but this size is typical
of many. (Later, when considering associated loci from specific
diseases that have been studied extensively, we simulated GWAS
of larger size.) To simulate a GWAS on a particular commercial
chip, we examined data at only those SNPs on the chip in question
and checked to see whether any of these SNPs showed a p-value
for association ,10
26. If this occurred we then modelled a
replication study, using an additional 2000 cases and 2000 controls
for definiteness. We took the best SNP from the simulated GWAS
and examined it in the simulated replication sample to check
whether it had p,0.01 in this replication sample. In what follows
we only considered those simulations where the best SNP on the
genotyping chip met both these criteria, as these model the
ascertainment implicit in reported GWAS associations. For these
simulations, we estimated the effect size at this associated SNP,
which we call the hit SNP, in the replication datasets and compared
it with the true effect size at the causal variant used for the
simulation. The fact that we estimate the effect size from the
replication data set is important, because it minimises the effect of
‘‘winner’s curse’’, which would otherwise lead to the effect sizes
being over estimated [4]. Simulated GWAS and replication
samples were generated for a range of assumed true effect sizes.
Reported genome-wide association studies differ in many
particular details, including the choice of genotyping chip used
and the sizes of the discovery and replication samples. Specific
assumptions are necessary for any simulation study, and ours aim
to capture the general features of many reported studies.
Investigation of different simulation scenarios, including different
genotyping chips and sample sizes, did not change the broad
conclusions that follow (data not shown).
Effect size estimates
To begin, we compare the estimated effect size at the replicated
hit SNP with the true effect size at the causal SNP in the
simulation. Figure 1 illustrates this comparison for three different
values of the true effect size. For each we see a peak of estimates
around the true effect size assumed at the causal SNP. But note
also that there is often underestimation of the true effect size (mean
estimated effect size 1.24, 1.86 and 3.32 for true relative risk of
1.25, 2 and 4 respectively), and that this underestimation can be
substantial when the true effect is large. For example, when the
true relative risk is 4, the estimated effect size was less than two in
12% of simulations of successful GWAS discovery of the effect.
In Figure 2 we plot the relative under- (or over-) estimation of
the effect size (estimated effect size divided by true effect size) as a
function of the correlation (as measured by the r
2 which is the
Author Summary
Genome-wide association studies (GWAS) exploit the
correlation in genetic diversity along chromosomes in
order to detect effects on disease risk without having to
type causal loci directly. The inevitable downside of this
approach is that, when the correlation between the marker
and the causal variant is imperfect, the risk associated with
carrying the predisposing allele is diluted and its effect is
underestimated. Using simulations, where we know the
true risk at the causal locus, we quantify the extent of this
underestimation. We show that, for loci which have a
modest effect on disease risk and are common in the
population, the risk estimated from the most associated
SNP is very close to the truth approximately two thirds of
the time. Although the extent of the underestimation
depends on assumptions about the frequency and
strength of the risk allele, we predict that fine mapping
of GWAS loci will, in rare cases, identify causal variants with
considerably higher risk. Using three common diseases
as examples, we investigate the expected cumulative
effects of underestimation at multiple loci on our ability to
stratify individuals by disease risk and to explain disease
heritability.
Figure 1. Distribution of estimated effect sizes. Histograms of estimated relative risks (RR), for three different true relative risks indicated by a
vertical dashed line in each plot. Histograms include all simulations where the most associated (hit) SNP was significant in both the initial study and
the replication study.
doi:10.1371/journal.pgen.1001337.g001
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and the true causal variant. The underestimation is seen to be due
to imperfect tagging: when the true causal variant is not well
tagged by SNPs on the genotyping chip (the correlation is weak),
the estimated effect at the hit SNP is often much lower than the
true effect. Conversely, when the causal SNP is well tagged by a
SNP on the chip, the estimated effects cluster around the true
effect size. Note that while underestimation decreases as the
correlation between the hit SNP and the causal SNP increases,
there remains systematic underestimation even when the hit SNP
has r
2<0.8 with the causative SNP. For example in one third of
simulations when the true effect is two, the estimated effect will be
under 1.8. Note also that when the true effect size is large,
significant and replicable associations can be detected when the
best tag SNP only has r
2<0.2 with the causal variant (Figure 2,
relative risk=4).
Imperfect tagging and an ascertainment effect also explain the
feature of the plots whereby the underestimation is much less for
smaller true effect sizes. If the true effect is small and the true
causal variant is not well-tagged on the genotyping chip, there will
not be enough power for the GWAS and subsequent replication to
reach significance [5], with the result that the corresponding
simulation will not contribute to the plot. But if the true effect is
large there may still be power to see a significant result when the
true variant is not well tagged, so the simulation contributes to the
plot and shows the underestimation. Put another way, if the true
effect is small, it will only be detected in an association study if the
causal SNP is well tagged, and in this case the effect size will be
estimated reasonably well. This second ascertainment effect
explains the lack of underestimation at hit SNPs not strongly
correlated to the causal SNP in the left panel of the Figure 2.
Lastly, as low frequency SNPs are less well tagged by other SNPs
[6], the extent of the underestimation also depends on the
frequency of the risk allele (see Figure S1). Interestingly, the effect
sizes at rare alleles are underestimated to a great extent, but only
when the true effect size is large enough for the tag SNP of a rare
allele to be detected and replicated in the simulated GWAS.
What true effects might underlie the effects estimated
from GWAS?
The results above describe the distribution of estimated effect
sizes as a function of known true effect sizes and the frequency of
the risk allele. In practice we are actually interested in the reverse
question, namely what true effect sizes are plausible in the light of
the effect size actually estimated from a GWAS and follow-up
study? We will see that this requires assumptions about the true
distribution of effect sizes. Indeed, writing RR for relative risk, and
RAF (risk allele frequency) for the allele frequency at the risk allele,
application of Bayes’ theorem gives
Pr true RR and RAFjobserved RR and RAF ðÞ !
Pr observed RR and RAFjtrue RR and RAF ðÞ |Pr true RR and RAF ðÞ ,
ð1Þ
where ‘‘true’’ refers to the value at the causal SNP and ‘‘observed’’
refers to the value at the hit SNP. Our simulation study allows us
to estimate the first factor on the right hand side of (1), and we do
so by discretising both the observed and true RR and RAF and
creating a matrix of counts based on our simulations over the
ENCODE regions. The second factor on the right hand side of (1)
is the assumed joint distribution of true risk allele frequencies and
effect sizes, which is of course unknown.
We proceed by making two different sets of assumptions about
these unknowns. In each case we assume that the distribution of
risk allele frequencies is given by the empirical distribution of allele
frequencies in the ENCODE regions. In effect this assumes that
any SNP variant is, a priori, equally likely to affect disease status.
What differs between the sets of assumptions is the assumed effect
size of a particular variant. Our first set of assumptions posits that
the distribution of effect sizes is the same for all putative causal
variants, regardless of their allele frequency, and that effect sizes
are close to those observed in GWAS studies. The second set of
assumptions explicitly assumes that there might be substantially
larger effects at variants with smaller minor allele frequency. These
priors are described in detail in the Methods section.
Different sets of assumptions about true effect sizes and risk
allele frequencies necessarily lead to different conclusions, and it is
impossible to study all possibilities. A number of theoretical
analyses [7,8,9,10] have argued for a relationship between effect
size, disease model, and minor allele frequency (MAF). As there is
no consensus on the exact form and extent of the relationship we
do not rely on them explicitly here, and instead our approach aims
to capture two different perspectives on unknown effect sizes, with
the subsequent analyses indicating a range of possibilities. The first
perspective is that the range of true effect sizes will be close to
those estimated from current GWAS. The second captures the
Figure 2. Relationship between underestimation and correlation. Scatter plots of the ratio of estimated to true relative risk against the
correlation (r
2) between the disease SNP and the hit SNP, for three different true relative risks. The horizontal dashed line indicates a ratio of 1. Points
below the line are under-estimated, and above are over-estimated. (Note that in the case where the hit SNP is also the causal SNP the correlation is 1.)
doi:10.1371/journal.pgen.1001337.g002
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larger effect sizes.
Under either set of assumptions, we can use our simulation study,
and Bayes’ Theorem (1) to estimate the conditional distribution of
true effect sizes and risk allele frequency (RAF) in the light of the
observed data at the GWAS hit SNP. Figure 3 illustrates this,
showing estimates of the posterior distribution of the true effect size
conditional on observing a risk estimate between 1.2 and 1.3, for
different observed risk allele frequencies, and under the two
different prior assumptions on effect size distributions.
A common feature of the histograms in Figure 3 is that the
mode of the posterior distribution on the true effect size is on, or
very closes, to the observed estimate. That is, current estimates
from GWAS studies of effect sizes from a common SNP, in the
range 1.2–1.3 are most likely to be very close to truth. As expected,
estimated effects within this range are more likely to be 1.3 than
1.2, because larger effects are more likely to generate a signal of
association strong enough to pass the p-value thresholds
commonly implemented in GWAS. This explains the left hand
tail of the distributions represented in Figure 3.
Figure 3 also shows that there is some probability that the effect
size at the causal variant is greater than estimated from the most
associated SNP. Interestingly, the observed risk allele frequency
impacts our posterior belief about the true effect size, under either
set of prior assumptions, with underestimation be more marked
when the risk allele at the hit SNP is rarer. Under the conservative
prior, when the risk allele at the hit SNP has less than 20%
frequency in the control population, the probability that the
relative risk is above 1.325 is 55%, compared to 35% when the risk
allele frequency is between 20–50%. The corresponding numbers
for the MAF-dependent prior are 77% and 49%. There are several
different phenomena at work here. If the hit SNP is the causal
SNP then, assuming that the association is strong enough to be
detected and replicated in the GWAS, there is no systematic under
estimation (and very little over estimation as we assume the effect
size is estimated from the replication sample). However,
conditional on the hit SNP not being causal, the distribution of
LD with true causal SNP, and therefore the propensity for under
estimation, depends on its allele frequency. The posterior
distribution on the true effect size given the observed frequency
and effect of the hit SNP can be viewed as a mixture of these two
scenarios, weighted by their conditional probability. Rarer SNPs
are less likely to be tagged well by single markers, and as noted
above, poor tagging leads to underestimation of effect sizes. In
contrast, for a common SNP, the associated allele is more likely to
be well correlated with the causal allele, so there is relatively less
under estimation. Under the MAF-dependent prior, when the
associated allele is low-frequency the causative allele will tend to
be low-frequency as well, and so potentially of larger effect. In the
scenario where we believe in larger effects at rare causal alleles and
have observed a SNP with low RAF with estimated relative risk
between 1.2 and 1.3 there is a 24% chance that the source of the
signal is a variant which actually doubles or more than doubles risk
with each copy of the risk allele.
Our observations are similar when the observed risk allele is the
most common allele in the population (RAF.50%) and therefore
Figure 3. Posterior distribution on true relative risk. Histograms showing the posterior distribution on the true relative risk (RR) conditional on
observing an estimated relative risk in the range 1.2–1.3 (vertical dashed lines). Left hand plots condition on the observed risk allele frequency (RAF)
being between 20 and 50%, while the right hand plots condition on a RAF less than 20%. Results are shown using two different priors on RR and RAF:
the blue histograms are the posterior distribution obtained using a conservative prior, and the red histograms are the posterior distribution obtained
using the MAF-dependent prior.
doi:10.1371/journal.pgen.1001337.g003
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conclusions also apply when the estimated effect size at the hit
SNP is weaker, for example in the range 1.05 to 1.2 (Figure S3).
Consequences for individual disease risk
One consequence of the potential underestimation of effect sizes
from GWAS findings is that as we move to better identification of
the actual causal variants, through fine mapping and/or functional
studies of associated regions, our estimates of their effect sizes
might well increase. Assuming a multiplicative model of risk across
loci, these small expected changes could combine to increase the
relative risk of disease in those individuals with highest genetic risk
of disease.
To investigate this, we simulated genotypes at known associated
loci in a population of individuals (assuming Hardy Weinberg
equilibrium and no linkage disequilibrium across loci) for each of
breast cancer, type 2 diabetes and Crohn’s disease, based on
reported risk allele frequencies [11,12,13] (see Tables S3, S4, S5
for a list of loci). First treating the causal loci and relative risks for
each disease as given by current GWAS estimates, we measured
the average risk of individuals in the top x%, by risk, of the
population (for differing values of x) and compared this to the
mean risk in the population. We then repeated this simulation,
allowing for the uncertainty in the estimation of true effect sizes by
averaging over the uncertainty in both the RAF and effect size of
the causal variant on the basis of the posterior distributions of
these, given the GWAS findings, under the two priors described
above. We assumed that risks combined multiplicatively across
loci. For NOD2 and IL23R in Crohn’s disease where the causal
variant is thought to be known, here and below, we used the effect
sizes for the known variant, and did not average over uncertainty
in these. Because all three diseases have been extensively studied,
we approximated the GWAS discovery process as corresponding
to a GWAS discovery sample of 5000 cases and 5000 controls, and
a replication sample of 10,000 cases and controls. The actual
discovery process for each of the diseases is complicated, often
involving meta-analysis and/or multistage discovery, and not
straightforward to model accurately, but the approach we use
should capture the fact that GWAS-discovery were ascertained
through study of large numbers of samples.
The results of the three simulations are given in Table 1.The
unadjusted simulations give estimates of how much more at risk
individuals with the greatest genetic propensity to disease are,
based only on GWAS loci, relative to the average person in the
population. As expected, the fold change in risk of individuals
carrying a large fraction of risk variants is dependent on the
number and magnitude of known loci. For example, individuals in
the top 0.1% of risk for Crohn’s disease are 20 times more likely
Table 1. Adjusted estimates of individual risks.
Type II Diabetes
x% 50 25 10 5 1 0.5 0.1
Unadjusted 1.31 1.58 1.92 2.17 2.73 2.96 3.49
(1.3–1.32) (1.56–1.6) (1.89–1.95) (2.12–2.21) (2.64–2.82) (2.85–3.1) (3.25–3.8)
Conservative 1.42 1.83 2.36 2.78 3.8 4.26 5.38
(1.36–1.52) (1.69–2.05) (2.12–2.77) (2.44–3.36) (3.19–4.9) (3.52–5.62) (4.25–7.58)
MAF-dependent 1.54 2.12 3.05 3.97 6.7 8.16 12.43
(1.41–1.74) (1.81–2.7) (2.34–4.74) (2.76–6.99) (3.75–15.08) (4.21–20.64) (5.26–43.06)
Crohn’s Disease
x% 50 25 10 5 1 0.5 0.1
Unadjusted 1.67 2.41 3.66 4.89 9.25 11.91 20.07
(1.64–1.7) (2.35–2.48) (3.53–3.79) (4.63–5.13) (8.39–10.31) (10.5–13.74) (15.88–27.04)
Conservative 1.78 2.71 4.28 5.82 11.2 14.56 25.41
(1.71–1.9) (2.52–3) (3.86–4.9) (5.18–6.81) (9.54–13.67) (12.04–18.24) (18.84–36.27)
MAF-dependent 2 3.36 6.01 8.87 19.77 27.19 54.11
(1.82–2.27) (2.83–4.26) (4.56–8.69) (6.29–14.13) (12.32–38.88) (15.91–58.84) (26.59–150.26)
Breast Cancer
x% 50 25 10 5 1 0.5 0.1
Unadjusted 1.2 1.38 1.58 1.71 2.02 2.14 2.4
(1.19–1.22) (1.36–1.4) (1.55–1.6) (1.68–1.74) (1.96–2.05) (2.05–2.19) (2.27–2.55)
Conservative 1.25 1.46 1.71 1.89 2.29 2.46 2.82
(1.2–1.33) (1.37–1.62) (1.57–1.99) (1.71–2.27) (2.02–2.92) (2.13–3.21) (2.39–3.9)
MAF-dependent 1.29 1.59 2.14 2.74 4.06 4.69 6.41
(1.2–1.5) (1.4–2.25) (1.64–4.25) (1.8–6.09) (2.14–11.12) (2.28–16) (2.58–36.14)
The median (and 95% confidence interval) of the increase in risk of individuals who are in the top x% of risk, relative to the average, for three common diseases. Values
are estimated (using 100,000 simulations of a population of 10,000 individuals) from a set of replicated associations (see Tables S2, S3, S4) using published point
estimates of the risk attributed to carrying a copy of the risk allele and its frequency in population controls. Unadjusted values use these numbers directly in the
simulation of individual risks. For the adjusted values we simulate the relative risk and risk allele frequency from its posterior distribution using two different priors:
conservative and MAF-dependent (see text).
doi:10.1371/journal.pgen.1001337.t001
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breast cancer, where the number of common loci and associated
relative risks is typically smaller, the equivalent number is just over
two-fold.
The second and third simulations attempt to average over the
possible outcomes of our future efforts to map causal mutations, to
reveal the likely gains in our ability to stratify individuals on the
basis of risk. These use the methodology above, under both prior
distributions, to average over the posterior distribution of the allele
frequency and effect size at the causal SNPs underlying reported
GWAS loci for the three diseases. These adjusted estimates are
also shown in Table 1. Across diseases we see that there is a
significant increase in the risk associated with carrying multiple
risk variants. In particular we see that the biggest differences in risk
are for those individuals in the extreme tail. It is these individuals
who carry the stronger, likely rarer, risk alleles which are currently
insufficiently characterised by the most significant signal of
association in some regions identified to be important in disease.
For example, the risk of an individual in the top 0.1% of the
population for genetic risk typed at the causal loci underlying
currently known GWAS loci will likely be increased by a factor of
3–6.5, 5–12, or 25–50, compared to an average individual, for
breast cancer, type 2 diabetes and Crohn’s disease. These are
notably greater increases in risk than current prediction based in
the hit SNPs from GWAS loci which would be 2.4, 3.5 and 20
respectively.
Missing heritability
We have shown above that as we move to identification of the
true causal variants underlying GWAS associations, through fine
mapping and functional studies, their effect sizes will tend to
increase, in a minority of cases substantially, compared to current
estimates from GWAS. This will, in turn, increase the amount of
heritability explained by these diseases. We can use the approach
developed here to try to quantify this effect.
We investigated this question in the context of the three diseases
just described, namely breast cancer, type 2 diabetes, and Crohn’s
disease. For each disease we took the set of hit SNPs from
published associated loci [11,12,13] (see Tables S3, S4, S5), and
for our two prior distributions on effect sizes we estimated the
posterior distribution of both the effect size and the allele
frequency for the causal SNP at each locus, as described in the
previous section. One commonly used measure of heritability is
sibling recurrence risk ratio, often denoted by lS: the relative
increase in risk to an individual if their sibling has the disease
compared to the baseline risk in the population as a whole [14].
Assuming, as is usual for heritability calculations [15], that there is
no interaction between loci, lS can be calculated as a function of
the risk allele frequency and effect size for each causal variant. In
order to allow for the uncertainty in the allele frequency and likely
underestimation of the effect size at the causal variants underlying
GWAS associations, we averaged this expression over the posterior
distribution of these quantities, given the GWAS findings (see
Methods for details).
The results are shown in Figure 4. For each disease they show
that the heritability due to already identified GWAS loci will be
higher than current estimates, under either set of assumptions
about true effect sizes, but particularly under the MAF-dependent
prior. Whereas at the time of writing the current estimates of the
contribution to lS from GWAS loci are 1.03, 1.08, and 1.49 for
breast cancer, type 2 diabetes, and Crohn’s disease, these may well
be 1.06, 1.14, and 1.61 (mean under the conservative prior) and
they could plausibly be as high as 1.21, 1.39 and 2.46 (mean under
the MAF-dependent prior). Whilst some of the ‘‘missing’’ heritability
Figure 4. Adjusted estimates of explained heritability. Cumu-
lative density functions of the posterior distribution of estimated sibling
recurrence risk ratio (estimated lS) in breast cancer (BC), Type 2
diabetes (T2D), and Crohn’s disease (CD) under the conservative and
MAF-dependent priors. The dotted line indicates the lS based on
replicated loci in each of the three diseases. The quoted values of
sibling recurrence risk ratio (lower right hand corner) are from
references given in main text. Posterior distributions were calculated
assuming a GWAS of 5,000 cases and controls and a replication study of
10,000 cases and controls.
doi:10.1371/journal.pgen.1001337.g004
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unlikely to account for the extent of the gap between estimates of
sibling relative risk (2, 1.8, and 10, respectively, from family studies
[16,17,18]) and those explained by currently known loci. We
return below to a discussion of the discrepancy.
Discussion
The correlation between alleles along the human genome has
allowed GWAS to look for regions associated with disease without
having to either genotype all known genetic variation or guess a
priori which regions of the genome may be important. Although
this approach has been a significant success, there is a predictable
downside of using a subset of variation to tag, or predict, untyped
diversity: for the vast majority of the SNPs identified as mediating
disease risk, we are left uncertain as to whether they are causally
involved in the pathway from genotype to phenotype, or, much
more plausibly, are just a surrogate for the causal variation.
GWAS associations will thus typically relate to a noisy
measurement of the causal variant. One consequence of this is
that the size of the genetic effect associated with GWAS loci may
be underestimated. We quantified this through an extensive
simulation study designed to mimic patterns of linkage disequilib-
rium in European Caucasian populations. We draw two broad
conclusions from these analyses. Firstly, a significant proportion of
estimated relative risks will be biased downwards because the hit
SNP is a powerful, but imperfect, tag for the true causal variation.
In most cases this effect will be relatively minor, but in some
instances, the best associated SNP may actually be a poor
predictor of a, putatively rarer, SNP with a much larger effect, in
which case the effect size estimated from the GWAS finding will
substantially underestimate the true effect size.
The exact proportion of reported associations which fall into
these two categories depends on properties of the design of the
study from which the SNP was identified, and on one’s belief
about how likely low frequency (.1%) variants of large effect are
to cause common diseases. The statistical power afforded by any
particular association strategy sets a lower limit on the size of effect
that can be under-estimated because an imperfect tag of an allele
with a small effect size will simply fail to achieve genome-wide
significance. Other properties of GWAS strategy, such as sample
ancestry and the number of markers typed, also change our
interpretation of observed effect sizes because they influence the
distribution of linkage disequilibrium between putative hit SNPs
and causal variants.
Our findings show that at any particular locus, especially if the
associated SNP has a low MAF, the true effect could be quite
large. But we would not expect this to be widespread. Were many
true effects this large it would be extremely surprising for so few of
them to have been observed: although any one such causal SNP
may not be well tagged on the genotyping chips used for GWAS,
some of them will happen to be at least moderately well tagged,
and their detection would lead to much larger estimates than have
been seen from current studies. In the context of this study these
early observations suggest that, of the two prior distributions we
investigated, it is the conservative prior that may better reflect the
true distribution of effect sizes attributed to low and common
frequency variants.
One way of viewing the posterior distribution on the true effects
shown in Figure 3 is as a probability distribution on the outcome of
efforts to fine map current regions of association. In this light, our
results inform questions of the design and value of fine mapping
experiments. First, simulations similar to those described above
(assuming causal variation to be distributed like SNPs in
ENCODE regions) suggest that less than 8% of the time will the
hit SNP actually be the causal SNP. We note that there may be
more reward in terms of gains in predictive ability and increases in
effect size from fine mapping SNPs with lower minor allele
frequency because they are, on average, more likely to be in poor
LD with an unobserved causal variant. On the other hand, our
simulations show that although they are unlikely to be causal, most
common hit SNPs are likely to be very good surrogates markers for
their causal variant. Indeed, in 25% of cases, the hit SNP will be a
near-perfect surrogate (ie r
2.0.99) for the causal variant. Should
this be the case, further genotyping will not reveal other SNPs with
stronger associations, unless sample sizes are extremely large.
Here we have quantified the increased spread of genetic risk
with genotypes just at known loci, and only considering a
multiplicative disease model. But even in this restricted setting,
there will be substantial differences in risk between high- and low-
risk groups based on these genetic factors. For example the
propensity of individuals in the top 0.1% of the population
distribution of genetic risk of type 2 diabetes will be increased by a
factor of 5–10, compared to the average. For breast cancer, in the
analogous top-risk group this risk will be increased by a factor of
3–5 (on the basis of common variation). Importantly, with the
growth of GWAS findings, both in terms of numbers of diseases
and numbers of loci for particular diseases, more and more of the
population will be in this most at risk category for at least one
disease: assuming 100 independent diseases, nearly 10% of the
population will be in the top 0.1% of risk of at least one disease.
Knowing which individuals these are and what diseases they are
most at risk of is therefore potentially useful information, both to
the individual and at the population level. The issues involved in
utilising such information in screening programmes (discussed for
example in [13]) are complicated, but our results strengthen the
arguments for consideration of this possibility.
We have shown that some of the ‘‘missing’’ heritability for
common disease actually resides in known GWAS loci and have
estimated this deficit for three particular diseases. While rather
more heritability is likely to be explained by known GWAS loci
than has been reported, this effect alone falls well short of
explaining all the missing heritability. Note, however, that there
are other reasons why existing loci may explain more heritability
than currently thought. Current calculations (by others, and
above) focus on a single causal variant in each associated region:
more variants within regions will explain more heritability. They
also ignore possible non-multiplicative disease effects, and also
ignore interactions between variants at different loci. Power to
detect either is low [19], so it is misleading to put much weight on
the failure of existing designs to find such effects. As others have
noted [20], parts of the missing heritability could be due to
multiple rare variants of large effect, associations with other forms
of genetic variation such as copy number polymorphisms, and
epigenetic effects. Indeed it would be surprising if each did not
play some role. Another possibility is that estimates of the
‘‘genetic’’ component of disease susceptibility, from epidemiolog-
ical studies, confound shared environment with shared DNA, and
so inflate heritability estimates [21,22].
Methods
Choice of genomic regions
In order to model the signal of association generated by disease-
causing mutations, we chose to simulate data exploiting empirical
surveys of human diversity. For this purpose we used data from the
10 ENCODE regions [23] within the CEU analysis panel of
HapMap II [5], which have undergone SNP ascertainment by
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therefore show a fuller spectrum of SNPs than are represented in
the HapMap data at large, and haplotypes are expected to be
accurate due to the trio design of the CEU HapMap panel [24].
The regions over which we simulate data are centred on each of
the 10 ENCODE regions (listed in Table S1) and include 500kb of
flanking HapMap variation at the boundaries of each region.
Simulation of population data
As the typical sample size of most GWAS is much larger than
the number of CEU HapMap individuals, we simulated 100,000
chromosomes using the HAPGEN software package. These
100,000 haplotypes we call the reference panel. GWAS case and
control samples were then subsampled from the reference panel, as
described below. HAPGEN uses a population genetic model that
incorporates the processes of mutation and fine-scale recombina-
tion to generate individuals from an existing set of known
haplotypes. We ran HAPGEN with an effective population size
of 11418 (as recommended for the CEU population), a population
scaled mutation rate of 1 per SNP, a population scaled
recombination rate from estimates described in [25], with the
known set of haplotypes taken from the CEU analysis panel of
HapMap II as described above (see http://www.stats.ox.ac.uk/
,marchini/software/gwas/hapgen.html).
Generating a case-control sample
For SNPs greater than 1% in frequency in the ENCODE
regions we performed two hypothetical GWAS by letting each of
the two alleles be causal in turn. We denote the causal allele by A
and the protective allele by a. To generate the control sample we
sampled the required number of haplotypes, without replacement,
from the reference panel and combined these in pairs to form
diploid individuals. This mimics the common use of population
controls, rather than controls explicitly chosen for not having the
disease under study. For the case sample, we sampled pairs of
haplotypes from the reference panel according to the genotype
frequencies at the causal SNP dictated by the assumed disease
model: If d is the risk of the AA genotype, and a is the risk of the Aa
genotype, both relative to the aa genotype, then we sample case
individuals (without replacement) on the basis of their genotypes at
the SNP assumed to be causal with success probabilities
proportional to:
p(AA)!df 2 p(Aa)!2af(1{f) p(aa)!(1{f)
2, ð2Þ
where f is the frequency of the risk allele A in the reference panel.
Throughout, for definiteness, we adopted a multiplicative model
for disease risk (additive on the log scale) defined by d=a
2.W e
refer to a as the relative risk (RR) or effect size associated with the
causal variant. To approximate a GWAS, we thinned the
generated data set to include only those SNPs present on the
Affymetrix 500K array that had a minor allele frequency in
sampled controls of greater than 1%. This set may or may not
include the assumed causal SNP.
For analyses involving only simulated data, we sampled 2,000
cases and 2,000 controls from the reference panel to emulate a
typical large GWAS. For the subsequent analyses of heritability
and individual risk profiling for type 2 diabetes, breast cancer and
Crohn’s disease that studied particular reported associations, we
simulated 5,000 cases and 5,000 controls to obtain results more
comparable to the size of study from which the associations were
ascertained. We simulated under a range of relative risks at 24 grid
points from 1.05 to 6. In attempting to simulate the signal of
disease at rare alleles (1% to 5%) in a GWAS of 5000 cases and
controls there were a small number of simulations in which there
were insufficient haplotypes in our reference panel to generate the
required number of genotypes at the causal SNP for large effect
sizes. These simulations were discarded, but as the numbers were
small (3% when the RR=4 and 11% when RR=6) we do not
believe this greatly affects the results presented below.
Testing for association
Following common practice, for each simulated case control
sample, we tested for association between genotype and case
control status using the Cochran Armitage trend test [26] at each
SNP with frequency greater than 1% in the simulated panel of
chromosomes. We calculated the p-value of this test statistic which
is x2 distributed with 1 degree of freedom under the null
hypothesis of no association. If any test across the region obtained
a p-value,10
26 the location of the most significant SNP (termed
the hit SNP) was recorded and we simulated this SNP in an
independent replication sample.
Simulating the replication processes
We simulated the replication experiment in three stages. First
we simulated the frequency of the causal allele in cases and
controls in the replication population. We then simulated the
frequency of the hit SNP conditional on the frequency of the
causal allele. Finally, we simulated the genotype counts for a
sample of cases and controls in this replication population.
We motivated sampling of the frequency of the causal allele in
controls in the replication population by thinking of the replication
sample as an additional sample from the same population as the
original GWAS sample. (Other assumptions are possible here, but
seem unlikely to affect the main conclusions.) Specifically, we
placed a uniform prior distribution on the unobserved population
frequency and sampled a value, f 9, from the posterior distribution
of this frequency given the data in the reference panel. (Given the
large size of the reference panel, the frequency in the replication
sample will be very close to that in the reference panel.)
Conditional on f 9, the population replication frequency in cases
was calculated from equation (2). To obtain the replication
population frequencies at the hit SNP we estimated the conditional
distribution in the reference sample of alleles at the hit SNP in
each of cases and controls, given those at the causal SNP, and used
these for the replication sample. This corresponds to assuming that
the LD between the causal and hit SNP in the replication sample
will be the same as that in the reference sample. Finally,
conditional on the population replication frequencies in cases
and controls, we take multinomial samples of the required size to
mimic the replication case and control samples. A test of
association using the trend test was performed at the hit SNP on
the simulated replication samples and deemed a significant
replication if the p-value was less than 10
22.
Estimating effect sizes
We estimate the effect size, or relative risk, a, at the hit SNP by
maximum likelihood under the model described above by
equation (2). For studies with population controls this can be
achieved in practice by fitting a logistic regression model for case
status [27].
Priors on effect size
We implement two different sets of prior assumption on the
effect size and its relationship with minor allele frequency. Our
first set of assumptions is that if a is the effect size at a causal
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standard deviation 0.2, independent of RAF. We refer to this as
the conservative prior, since it places little weight on relative risks
greater than 1.5. To get a sense for this distribution, it assumes that
81% of true effect sizes are less than 1.3 with 96% less than 1.5,
and 99.9% less than 2. A further discussion of the choice of prior
on effect sizes can be found in [19] and [28].
Our second set of assumptions, which we call the MAF-dependent
prior, again assumes a normal distribution for log(a) with mean 0,
but here the standard deviation, s, is allowed to depend on the
RAF. The dependence of the distribution of the effect size on allele
frequency has no theoretical justification, but is chosen on
pragmatic grounds to give a gradual increase in the average effect
size as the alleles at causal SNP become rarer in the population. It
is implemented by increasing s by a weight defined by an
exponential density with parameters chosen such that, when the
RAF is near 0.5 (a common SNP), this prior is approximately
the same as the conservative prior, with s=0.2. As the RAF
approaches 0 or 1 (corresponding to rarer SNPs), then con-
siderably more weight is put on larger RRs. See Figure S4 and
Table S2 for details. For example, when the MAF is less than 5%
the second prior gives an approximately 45% chance that the risk
associated with each copy of the causal allele is larger than 2.5.
Note that we used an empirical prior on the frequency of the risk
allele (Figure S5) by choosing each allele, at each SNP, with in the
ENCODE region to be causal in turn.
Estimating heritability
A commonly used measure of heritability is based on con-
sidering the risk of disease to an individual j conditional on them
having an affected (Y~1) sibling k relative to the unconditional










We can calculate the above, using assuming that
Pr(Yk~1)~Pr(Yj~1), and by summing over the genotypes
















If we divide through by the square of the risk associated with most
protective genotype (which we can define to be g~0) then we can
write the above in terms of the per allele relative risk a, and assume
the genotype probabilities follow Hardy-Weinberg equilibrium




2,P r ( g1)~2f|(1{f), Pr(g2)~f 2
By making the further assumption that loci are independent
an estimate of the heritability explained by a set of hit SNPs
can be obtained by multiplying together the lS values calculated at
each individual locus. We calculated sibling relative risk in this
manner using estimates of RR and RAF of replicated loci from
studies of Type 2 diabetes, Crohn’s disease and breast cancer (see
Tables S3, S4, S5).
We then simulated 100,000 times from the posterior of true RR
and RAF of each locus conditional upon the reported RR and
RAF, using the simulation approach and the two different priors as
described in the paper. For each set of simulations, for each
disease, we recalculated lS at each locus and multiplied over loci,
giving a sample from the posterior distribution of sibling risk that
could be explained by the current set of report loci if the causal loci
where typed directly.
Supporting Information
Figure S1 Average relative underestimation of effect size as a
function of allele frequency and true effect size. Line plot shows the
mean ratio of the effect size estimated from the most associated
GWAS SNP to the true effect size at the causal locus. Lines are
shown for 4 different risk allele frequency (RAF) bins.
Found at: doi:10.1371/journal.pgen.1001337.s001 (0.01 MB EPS)
Figure S2 Posterior distribution on true relative risk when the
minor allele is protective. Histograms showing the posterior
distribution on the true relative risk (RR) conditional on observing
an estimated relative risk and risk allele frequency (RAF) at the hit
SNP. Results are shown using two different priors on RR and
MAF: the blue histograms are the posterior distribution obtained
using a conservative prior, and the red histograms are the posterior
distribution obtained using the MAF-dependent prior.
Found at: doi:10.1371/journal.pgen.1001337.s002 (0.92 MB EPS)
Figure S3 Posterior distribution on true relative risk for low
estimated effect sizes. Histograms showing the posterior distribu-
tion on the true relative risk (RR) conditional on observing an
estimated relative risk and risk allele frequency (RAF) at the hit
SNP. Results are shown using two different priors on RR and
MAF: the blue histograms are the posterior distribution obtained
using a conservative prior, and the red histograms are the posterior
distribution obtained using the MAF-dependent prior.
Found at: doi:10.1371/journal.pgen.1001337.s003 (0.92 MB EPS)
Figure S4 Priors on relative risks. Probability distributions of
relative risk as a function of minor allele frequency for the MAF-
dependent and conservative priors (the blue line). The MAF-
dependent prior is pictured for five values of MAF
Found at: doi:10.1371/journal.pgen.1001337.s004 (3.14 MB EPS)
Figure S5 Empirical prior on risk allele frequency. Cumulative
distribution of the frequency of SNPs within the ENCODE regions
used for simulations. At each SNP, each allele is chosen is turn
chosen to be the risk allele so the distribution is symmetric around
a half.
Found at: doi:10.1371/journal.pgen.1001337.s005 (3.14 MB EPS)
Table S1 ENCODE regions used in simulations. The build 35
coordinates of the regions of HapMap CEU data used by HapGen
to simulate genome-wide association study data. When simulating
haplotypes and testing for association a 500kb buffer window was
included either side of the listed regions.
Found at: doi:10.1371/journal.pgen.1001337.s006 (0.03 MB
DOC)
Table S2 MAF dependent prior. Table of the standard deviation
of the prior distribution of the log relative risk (RR) as a function of
risk allele frequency (RAF).
Found at: doi:10.1371/journal.pgen.1001337.s007 (0.06 MB
DOC)
Table S3 SNPs for Type 2 diabetes. (See main text for reference).
Found at: doi:10.1371/journal.pgen.1001337.s008 (0.04 MB
DOC)
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for reference).
Found at: doi:10.1371/journal.pgen.1001337.s009 (0.05 MB
DOC)
Table S5 Replicated SNPs for breast cancer. (See main text for
reference).
Found at: doi:10.1371/journal.pgen.1001337.s010 (0.03 MB
DOC)
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